Clinical trials: Non-muscle-invasive Bladder Cancer
Bladder Cancer, CIS
A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)
The purpose of this study is to observe and describe the effectiveness and local tolerability of intravesical treatment with valrubicin for non-muscle invasive bladder cancer (NMIBC) in a cohort of subjects treated under routine…
- Trial name
- NCT01314664
- Where
- 11 sites in United States
- Volunteers
- 15 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Non Muscle Invasive Bladder Cancer
Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer
The treatment of non-muscle invasive bladder cancer (NMIBC) is problematic given the variable natural history of the disease. Although contemporary treatment options are limited, new targets and new approaches are under…
- Trial name
- NCT02343614
- Testing
- Celecoxib
- Volunteers
- 58 people
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Bladder Cancer
PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer
Approximately 25 subjects will be enrolled and receive a standard WHO adult potency BCG immunization (1cc/50mg live mycobacilli) in the deltoid.
- Trial name
- NCT02326168
- Testing
- Bacillus Calmette-Guerin (BCG)
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Bladder Neoplasms
Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer
This study is designed to assess the safety and preliminary efficacy of five different doses of DTA-H19 given as six intravesical infusions into the bladder of patients with superficial bladder cancer who have failed intravesical…
- Trial name
- NCT00393809
- Testing
- DTA-H19
- Where
- 2 sites in Israel
- Volunteers
- 18 people
- Sponsor
- Hebrew University of Jerusalem
Urinary Bladder Neoplasms
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
Background: Non-muscle-invasive bladder cancer is in the early stages. But it usually comes back after treatment. The drugs Vicineum and Durvalumab may help the immune system find and destroy cancer cells.
- Trial name
- NCT03258593
- Testing
- Durvalumab, Vicineum, Acetaminophen
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)
This multicenter, prospective, single-arm, phase 3 study will assess the proportion of disease-free patients, starting from administration of the first study treatment to at least 12-months after the first treatment, and up to 2…
- Trial name
- NCT02471495
- Testing
- Synergo® RITE + MMC
- Sponsor
- Medical Enterprises Europe B.V.
Bladder Cancer, Non-muscle-invasive Bladder Cancer
Pre-Habilitation with Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)
The PRIMER (Pre-Habilitation With Mindfulness and Exercise for Patients Undergoing Radical Cystectomy) trial is a pilot designed to estimate the feasibility of integrating a home-based pre-operative exercise and mindfulness…
- Conditions
- Bladder Cancer, Non-muscle-invasive Bladder Cancer, Muscle-Invasive Bladder Carcinoma
- Trial name
- PRIMER (NCT05790850)
- Testing
- Pre-operative physical exercise, Pre-operative mindfulness meditation practice
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Virginia
Non-muscle Invasive Bladder Cancer
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer.
- Trial name
- CREST (NCT04165317)
- Testing
- PF-06801591, Bacillus Calmette-Guerin
- Where
- 196 sites in United States, Australia and 12 more
- Volunteers
- 1,068 people
- Sponsor
- Pfizer
Non-Muscle Invasive Bladder Cancer
Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
A phase III multi-center randomized, double-blind and positive-controlled clinical trial for evaluating the efficacy and safety of BCG for Therapeutic Use（BCG） in the prevention of postoperative recurrence of medium/high-risk…
- Trial name
- NCT06241755
- Testing
- BCG for Therapeutic Use
- Where
- China
- Volunteers
- 412 people
- Sponsor
- Chengdu CoenBiotech Co., Ltd
Non-muscle Invasive Bladder Cancer (NMIBC)
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.
- Trial name
- NCT07187063
- Testing
- UroAmp Test (Convergent Genomics, Inc.)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Lahey Clinic
HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT
RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients
This study is an open, single-arm, single-center exploratory clinical study to explore the efficacy and safety of Disitamab Vedotin (RC-48) in combination with radiotherapy for the treatment of patients with HER2-expressing…
- Trial name
- NCT07100184
- Testing
- Disitamab Vedotin combined with Radiotherapy
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Non Muscle-invasive Bladder Cancer
Evaluation of Immediate Preoperative Instillation (IPOI) of Mitomycin C Compared to Early Postoperative Instillation (IPOP) in Non-muscle Invasive Bladder Cancer
This study seeks to optimize the management of TVNIM (reduction of the risk of reccurence of the disease) by comparing in terms of efficacy and tolerance the immediate preoperative administration of mitomycin C (IPOI) to an early…
- Trial name
- NCT02075060
- Testing
- IPOI, IPOP
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Poitiers University Hospital
Intermediate and High-risk Non-muscle Invasive Bladder Cancer
A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-2005 for Intravesical perfusion in patients with intermediate and high-risk non-muscle…
- Trial name
- NCT06108492
- Testing
- SHR-2005
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Non Muscle Invasive Bladder Cancer
A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)
This study is a prospective randomized open labeled dose ranging comparative study. Twenty four (24) patients with NMIBC who meet the inclusion/exclusion criteria will be recruited for the study following the initial diagnostic…
- Trial name
- NMIBC TURBT HG (NCT01799499)
- Testing
- TC-3 hydrogel
- Where
- Israel
- Sponsor
- UroGen Pharma Ltd.
NMIBC
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) who are BCG Naïve or BCG Unresponsive and are considered ineligible for or have refused to undergo radical cystectomy, will receive RC48-ADC in…
- Trial name
- NCT05943379
- Testing
- RC48-ADC in Combination with gemcitabine
- Where
- China
- Volunteers
- 85 people
- Sponsor
- RemeGen Co., Ltd.
Bladder Cancer TNM Staging Primary Tumor (T) Ta, Bladder Cancer TNM Staging Primary Tumor (T) T1
Intravesical Adjuvant Electromotive Mitomycin-C
In laboratory and clinical studies, intravesical electromotive drug administration increased mitomycin bladder uptake, improving clinical efficacy in high-risk non-muscle invasive urothelial bladder cancer.
- Conditions
- Bladder Cancer TNM Staging Primary Tumor (T) Ta, Bladder Cancer TNM Staging Primary Tumor (T) T1, Bladder Cancer Transitional Cell Grade
- Trial name
- EMDA/MMC (NCT01920269)
- Testing
- Trans-urethral resection, intravesical passive diffusion mitomycin, intravesical electromotive mitomycin
- Where
- Italy
- Volunteers
- 331 people
- Sponsor
- University of Rome Tor Vergata
Bladder Cancer, Recurrent Bladder Cancer
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
Bladder cancer is the most common urinary tract cancer and the 6th most common cancer in the US. Yet bladder cancer research is underfunded relative to other common cancers.
- Conditions
- Bladder Cancer, Recurrent Bladder Cancer, Non-muscle Invasive Bladder Cancer (NMIBC)
- Trial name
- CISTO2 (NCT07225127)
- Where
- 6 sites in United States
- Volunteers
- 408 people
- Sponsor
- University of Washington
Bladder Cancer
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer
The purposes of this study are to: find out whether participants' cancer returns or gets worse while they are taking lenalidomide and Bacille Calmette-Guerrin (BCG); evaluate the safety and tolerability of the combination of…
- Trial name
- NCT01373294
- Testing
- Bacille Calmette-Guerrin (BCG), Lenalidomide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-Muscle Invasive Bladder Cancer, HER2
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
This is a prospective, open, single-center clinical study of anti-HER2-ADC combined with PD-1 monoclonal antibody for bladder sparing treatment in non-muscular invasive bladder cancer (NMIBC) patients with HER2-expressing.
- Trial name
- NCT05957757
- Testing
- RC48, Tislelizumab
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Transurethral Resection of Bladder Tumor
Evaluation of the Role of Early Second Look TURBT in Management of High Risk Non Muscle Invasive Bladder Cancer
The aim is to evaluate the intraoperative, postoperative and pathologic findings of early second look TURBT and the factors affecting these findings to assess the value of early second TURBT in the management of high risk NMIBC.
- Trial name
- NCT07642102
- Testing
- early second look transurethral resection of bladder tumor
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Ain Shams University